The effect of intraileal infusion of fat emulsions, differing in degree of saturation, on satiety and food intake after a liquid meal replacement.

1. Signed informed consent form;

2. Sex: male or female;

3. Age: 18-55 years;

4. Body Mass Index (BMI): 18-32 kg/m2.

1. Evidence of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol;

2. Gastrointestinal or hepatic disorders influencing gastrointestinal absorption or transit;


3. The use of psychotropic drugs, including: benzodiazepines or alcohol in excess of 21 units/week for males and 14 units/week for females;


4. Concomitant medication that can increase gastric pH (e.g. antacids, protonpump-inhibitors, prostaglandins, anticholinergic agents, H2-receptor antagonists), or alter gastric emptying (e.g. metoclopramide, cisapride, domperidone and erythromycin, anticholinergics, tricyclic antidepresants, narcotic analgetics, adrenergic agents, calcium channel blockers), or alter intestinal transit (e.g. loperamide, chemical/osmotic/bulk laxatives) ,or influence satiety/energy intake (e.g. sibutramine, glucocorticoids, anabolic steroids);


5. Intolerance of Slim Fast product or of ingredients of the ad libitum meal;


6. Pregnancy, lactation, wish to become pregnant during study, or having a positive pregnancy test at inclusion;


7. Reported unexplained weight loss/gain of more than 2 kg in the month before the study enrollment.